Last updated: 11/03/2018 07:45:15
Evaluation of the immunogenicity, safety and reactogenicity of the combined DTPa-IPV vaccine in healthy infants
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A multicentric study to compare the immunogenicity, safety & reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs. co-administration of GSK's DTPa vaccine & Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children
Trial description: DTPa and IPV vaccines are recommended for immunization of infants in Korea. The use of combination vaccines simplifies routine paediatric vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Number of seroprotected subjects against diphtheria (anti-D) and tetanus (anti-T)
Timeframe: One month (Month 5) post-primary vaccination course
Number of seroprotected subjects against poliovirus (anti-polio) types 1, 2 and 3
Timeframe: One month (Month 5) post-primary vaccination course
Number of subjects with a vaccine response for anti-pertussis toxoid (anti-PT), anti-pertactin (anti-PRN) and anti-filamentous haemagglutinin (anti-FHA)
Timeframe: One month (Month 5) post-primary vaccination course
Number of subjects with vaccine response to pertussis toxoid (PT), pertactin (PRN) and filamentous haemagglutinin (FHA) antigens
Timeframe: One month (Month 5) post-primary vaccination course
Secondary outcomes:
Number of seroprotected subjects against diphtheria (anti-D) and tetanus (anti-T)
Timeframe: Before (Pre) and one month after (Post) the primary vaccination course
Concentration of antibodies against diphteria (anti-D) and tetanus (anti-T)
Timeframe: Before (Pre) and one month after (Post) the primary vaccination course
Titers for poliovirus type 1, 2 and 3 antibodies
Timeframe: Before (Pre) and one month after (Post) the primary vaccination course
Concentrations of antibodies against pertussis toxoid (anti-PT), pertactin (anti-PRN) and filamentous haemagglutinin (anti-FHA)
Timeframe: Before (Pre) and one month after (Post) the primary vaccination course
Number of subjects reporting solicited local symptoms
Timeframe: During the 4-day (Days 0-3) post-vaccination period, across doses
Number of subjects reporting solicited general symptoms
Timeframe: During the 4-day (Days 0-3) post-vaccination period, across doses
Number of subjects reporting any unsolicited adverse events (AEs)
Timeframe: During the 31-day (Days 0-30) post-vaccination period
Number of subjects reporting any serious adverse events (SAEs)
Timeframe: During the entire study period (from Month 0 up to Month 5)
Interventions:
Biological/vaccine: DTPa-IPV
Biological/vaccine: DTPa
Biological/vaccine: IMOVAX Polio®
Enrollment:
458
Observational study model:
Not applicable
Primary completion date:
2007-23-01
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Tetanus, acellular pertussis, Diphtheria
Product
SB213503
Collaborators
Not applicable
Study date(s)
January 2006 to January 2007
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
8 - 12 weeks
Accepts healthy volunteers
Yes
- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol .
- A male or female between, and including, 8 and 12 weeks (56-90 days) of age at the time of the first vaccination.
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol .
- A male or female between, and including, 8 and 12 weeks (56-90 days) of age at the time of the first vaccination.
- Written informed consent obtained from the parent or guardian of the subject.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Born after a gestation period of 36 to 42 weeks inclusive.
Exclusion criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
- Administration of any vaccine within 30 days (i.e.30 days to 1 day) before the first dose of the study vaccine.
- Planned administration/ administration of a vaccine not foreseen by the study protocol during the study period (i.e. Day 0 to Month 7), with the exception of Bacille Calmette-Guérin (BCG) vaccine, hepatitis B vaccine, pneumococcal vaccine, flu vaccine and Hib vaccine.
- Planned administration/ administration of a vaccine foreseen by the study protocol (i.e. BCG vaccine, hepatitis B vaccine, pneumococcal, flu vaccine and Hib vaccine) during the period 30 days before and one week after the study vaccine dose.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- Previous vaccination against diphtheria, tetanus, pertussis and/or poliovirus disease.
- History of diphtheria, tetanus, pertussis and/or poliovirus diseases.
- Known exposure to diphtheria, tetanus, pertussis and/or poliovirus before the study period.
- Any anaemia/ thrombocytopenia or blood clot that leads to prohibition from intramuscular injection.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- A family history of congenital or hereditary immunodeficiency.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).
- Major congenital defects or serious chronic illness.
- History of any neurologic disorders or seizures.
- Acute disease at the time of enrolment
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2007-23-01
Actual study completion date
2007-23-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website